Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)

“Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with metastatic hormone-refractory prostate cancer (HRPC). The study, referred to as the SHIP (Selinexor in Hormone Refractory Indications in Prostate Cancer) study, is led by Drs. Christopher J. Logothetis and John Araujo of the M.D. Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.”

Editor’s note: This story describes a new clinical trial to test a prostate cancer treatment in volunteer patients. The new drug is called Selinexor (aka KPT-330), and it may benefit patients who have been diagnosed with metastatic hormone-refractory prostate cancer.